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Introduction
Immunogenicity of anti-Tumor Necrosis Factor agents
is one of the mechanisms behind treatment failure.
Objectives
To explore the relationship between the presence of
antiadalimumab antibodies (AAA), the disease activity
and the therapeutic decisions.
Methods
Cross-sectional retrospective study determining: 1)
serum adalimumab (Ada) levels by a capture ELISA
(positive > 5 ng/ml) and 2) levels of AAA by a two-site
bridging ELISA [positive > 10 Arbitrary Units (AU)/ml].
The clinical activity was assessed by conventional tests
and the physician visual analogue scale (ph-VAS) of 0 to
10, the same day that the blood sample was collected.
Blood samples were obtained a few hours before drug
administration.
Results
Until March 2013 measurements in 25 patients were
available, 15 (60%) of them had some activity of their dis-
ease ph-VAS = 1.7 ± 0.9 (1-4). Eight (32%) children pre-
sented AAA, range from 12 to 30,000 AU/ml, and
absence of Ada levels. All cases with AAA positives had
active disease, except one who had received a periocular
corticosteroid injection in the previous month. Further-
more 8/17 (47%) patients without AAA had active dis-
ease. The duration disease and the age were not different
between those with and without AAA. The only clinical
and analytical difference was the higher frequency of
active uveitis when AAA were present (p = 0.01). Simi-
larly median survival time on treatment was shorter
when AAA were present (2.3 vs 2.5 years) (p = 0.03).
Conclusion
Antiadalimumab antibodies appear to explain half of the
cases of active disease and their presence is associated
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Table 1 Characteristics of 25 children with pediatric
rheumatic diseases treated with Adalimumab.



























13 (77) 3 (18) 5 (29) 6
(35)
4 (24)
Data are expressed as n (%)
AAA = Antiadalimumab antibodies; JIA = Juvenile Idiopathic Arthritis; ANA =
Antinuclear antibodies; MTX = Concomitant Methotrexate.
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